GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Plus Therapeutics (Plus Therapeutics) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Plus Therapeutics  (NAS:PSTV) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Plus Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics (Plus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
MRZM RNAZ ELAB IKT CLDI DOMH ONVO MBRX RASP ERNA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XMP0:Germany
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Website
https://www.plustherapeutics.com
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director